$Syndax Pharmaceuticals (SNDX.US)$Reuters· 11 mins ago Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups
$Syndax Pharmaceuticals (SNDX.US)$But im sure/hoping Dr@Jaguar8will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation 1 HOUR AGO, 5:29 PM EST VIA PR NEWSWIRE – Approva...
2
6
Report
Jaguar8
:
It is a big deal indeed because it’s first of its kind for adult and especially for pediatric cases.
$Syndax Pharmaceuticals (SNDX.US)$ Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Trytosaveabit
OPDaily Investors
:
If you’re asking if I keep up with FDA PDUFA calendar and such! Yes! I actually make a lot of reminder posts to followers saying ( PDUFA date on such and such )
$Syndax Pharmaceuticals (SNDX.US)$ Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib Syndax Pharmaceuticals (SNDX)announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profil...
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Syndax Pharmaceuticals Stock Forum
Can Syndax's $7.7M Revuforj Launch Offset Rising Expenses? Q4 Earnings Reveal Strategy
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Syndax Pharmaceuticals (SNDX)announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profil...
Syndax Pharmaceuticals Inc - Primary Endpoint Met With 23% Cr/CRH Rate in Phase 2 Trial
Dow Jones· 1 min ago
No comment yet